In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Profitability: A Mixed Blessing for Celltech

Executive Summary

Celltech's early profits have come from unexciting, low growth specialty pharma products rather than from a breakthrough in its innovative biotechnology pipeline. Now, the challenge for new CEO Göran Ando is to prove that Celltech's focus remains R&D, not specialty pharmaceuticals. With few promising late-stage in-house projects other than CDP 870, generic threats to the revenue source, and the straitjacket that comes with profitability, Ando has plenty on his plate. But his experience, both broadly within the industry and with CDP 870 in particular, suggest he's well placed to take Celltech to a new level of profitability.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts